Andrew Sharabi

Title(s)Associate Professor Of Clinical, Radiation Medicine and Applied Science
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Johns Hopkins HospitalResidency2015Radiation Oncology
    Baylor College of MedicineM.D.2010Medicine
    Baylor College of MedicinePh.D.2009Immunology
    University of California at San DiegoB.S.2001Bioengineering
    Collapse Awards and Honors
    University of California at San Diego2020Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award
    University of California at San Diego2019Academy of Clinician Scholars Whitehill Award for Excellence in Teaching
    American Cancer Society2019American Cancer Society (ACS) Cancer Care Champion - Radiation Oncologist of the Year
    University of California at San Diego2017UCSD ACTRI KL2 Translational Science Award
    Johns Hopkins University2015Roentgen Resident/Fellow Research Award
    Johns Hopkins University2015American Society for Radiation Oncology (ASTRO) Travel Award
    Johns Hopkins University2014American Society for Radiation Oncology (ASTRO) Resident Clinical Basic Science Research Award
    Johns Hopkins University2013ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant
    Johns Hopkins University2012John G. Rangos Medal of Honor for Creativity in Cancer Discovery
    Baylor College of Medicine20081st Place Talk, MD/PhD Program Annual Symposium
    Baylor College of Medicine20071st Place Talk, Immunology Department Annual Symposium
    Baylor College of Medicine20072nd Place Poster, Center for Cell and Gene Therapy Conference
    Baylor College of Medicine20062nd Place Poster, Immunology Department Annual Symposium
    Baylor College of Medicine20062nd Place Talk, Center for Cell and Gene Therapy Conference
    Baylor College of Medicine2003BCM M.D./Ph.D. Program Academic Achievement Award
    University of California at San Diego2001Bioengineering Department Highest Academic Achievement Award
    University of California at San Diego2001Summa Cum Laude
    University of California at San Diego2000Phi Beta Kappa National Honor Society
    University of California at San Diego 1997  - 2001Provost's Honors

    Collapse Overview 
    Collapse Overview
    Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He sees patients at the La Jolla Moores Cancer Center and his specialties include Prostate (Genitourinary) and Head and Neck Cancers. He treats patients with novel radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). Dr. Sharabi serves as Director of the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center and is Chair of the American Society of Therapeutic Radiology and Oncology (ASTRO) Education Committee - Immunotherapy Track.

    Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. He is the PI of multiple investigator initiated clinical trials combining radiation therapy with anti-PD-1 immunotherapy and has published his work in top journals including Nature Communications and Lancet Oncology. His NIH funded laboratory in the Moores Cancer Center focuses on development of novel immunotherapies and strategies to combine radiation with immunotherapy.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy
    NIH R21CA256360Jan 1, 2021 - Dec 31, 2022
    Role: Principal Investigator
    Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC
    NIH/NIDCR R01DE028563Apr 1, 2019 - Mar 31, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers. Cancers (Basel). 2022 Dec 25; 15(1). Saidian A, Dolendo I, Sharabi A, Stewart TF, Rose B, McKay RR, Bagrodia A, Salmasi A. PMID: 36612124; PMCID: PMC9818005.
      View in: PubMed   Mentions: 2  
    2. Germline genetic biomarkers to stratify patients for personalized radiation treatment. J Transl Med. 2022 08 12; 20(1):360. Deichaite I, Hopper A, Krockenberger L, Sears TJ, Sutton L, Ray X, Sharabi A, Navon A, Sanghvi P, Carter H, Moiseenko V. PMID: 35962345; PMCID: PMC9373374.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    3. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun. 2022 07 25; 13(1):4298. Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. PMID: 35879302; PMCID: PMC9314425.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    4. Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nat Commun. 2022 07 05; 13(1):3869. Hingorani DV, Allevato MM, Camargo MF, Lesperance J, Quraishi MA, Aguilera J, Franiak-Pietryga I, Scanderbeg DJ, Wang Z, Molinolo AA, Alvarado D, Sharabi AB, Bui JD, Cohen EEW, Adams SR, Gutkind JS, Advani SJ. PMID: 35790753; PMCID: PMC9256669.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    5. Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data. Clin Cancer Res. 2022 05 02; 28(9):1832-1840. Williamson CW, Nelson TJ, Thompson CA, Vitzthum LK, Zakeri K, Riviere PJ, Bryant AK, Sharabi AB, Zou J, Mell LK. PMID: 35140122.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. Mol Cancer Ther. 2022 04 01; 21(4):616-624. Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS. PMID: 35086958; PMCID: PMC8983493.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    7. Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. Cancer. 2022 05 15; 128(10):1948-1957. Nelson TJ, Thompson CA, Zou J, Kumar A, Sangchan P, Williamson CW, Vitzthum LK, Sharabi AB, Murphy JD, Fakhry CA, Mell LK. PMID: 35194791.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther. 2022 07; 235:108114. Joshi S, Sharabi A. PMID: 35122833; PMCID: PMC9189042.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    9. Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics. J Nucl Med. 2022 07; 63(7):1087-1093. Yusufaly TI, Zou J, Nelson TJ, Williamson CW, Simon A, Singhal M, Liu H, Wong H, Saenz CC, Mayadev J, McHale MT, Yashar CM, Eskander R, Sharabi A, Hoh CK, Obrzut S, Mell LK. PMID: 34711618; PMCID: PMC9258568.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Adaptive replanning using cone beam CT for deformation of original CT simulation. J Med Radiat Sci. 2022 Jun; 69(2):267-272. Bojechko C, Hua P, Sumner W, Guram K, Atwood T, Sharabi A. PMID: 34704381; PMCID: PMC9163453.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Split course palliative radiotherapy for advanced lung cancer with 3D planning based analysis of outcome: a retrospective review. Ann Palliat Med. 2022 Feb; 11(2):423-430. Bruggeman AR, Sarkar RR, Ahn GS, Fuster EI, Dornisch A, Sharabi AB, Murphy JD, Sandhu AP. PMID: 34775767.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Hypofractionated radiation therapy as palliative management for symptomatic and local control of advanced thoracic malignancies. Ann Palliat Med. 2021 10; 10(10):10360-10368. Ahn GS, Bruggeman AR, Qiao EM, Moiseenko V, Ray X, Sharabi A, Murphy JD, Sandhu AP. PMID: 34670382.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Front Oncol. 2021; 11:738626. Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. PMID: 34621678; PMCID: PMC8490924.
      View in: PubMed   Mentions: 4  
    14. Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):514-528. Franiak-Pietryga I, Miyauchi S, Kim SS, Sanders PD, Sumner W, Zhang L, Mundt AJ, Califano JA, Sharabi AB. PMID: 34474108; PMCID: PMC8976465.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    15. End of treatment cone-beam computed tomography (CBCT) is predictive of radiation response and overall survival in oropharyngeal squamous cell carcinoma. Radiat Oncol. 2021 Aug 09; 16(1):147. Sumner W, Kim SS, Vitzthum L, Moore K, Atwood T, Murphy J, Miyauchi S, Califano JA, Mell LK, Mundt AJ, Sharabi AB. PMID: 34372887; PMCID: PMC8351145.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082. Kim SS, Sumner WA, Miyauchi S, Cohen EEW, Califano JA, Sharabi AB. PMID: 34230025; PMCID: PMC8976464.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    17. Scirrhous carcinoma: A previously undescribed tumor of the oral cavity. Clin Case Rep. 2021 May; 9(5):e03864. DeVries J, Finegersh A, Gold KA, Sharabi AB, Hu J, Orosco RK. PMID: 34084475; PMCID: PMC8142303.
      View in: PubMed   Mentions:
    18. Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature. Front Oncol. 2021; 11:662954. Riviere P, Sumner W, Cornell M, Sandhu A, Murphy JD, Hattangadi-Gluth J, Bruggeman A, Kim SS, Randall JM, Sharabi AB. PMID: 33996587; PMCID: PMC8121173.
      View in: PubMed   Mentions: 8  
    19. Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer. 2021 05 15; 127(10):1553-1567. Williamson CW, Sherer MV, Zamarin D, Sharabi AB, Dyer BA, Mell LK, Mayadev JS. PMID: 33620731; PMCID: PMC9376883.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    20. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    21. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. Semin Radiat Oncol. 2020 10; 30(4):273-280. Feng CH, Mell LK, Sharabi AB, McHale M, Mayadev JS. PMID: 32828383.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    22. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):396-412. Dyer BA, Feng CH, Eskander R, Sharabi AB, Mell LK, McHale M, Mayadev JS. PMID: 32942005.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    23. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422; PMCID: PMC7541603.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    24. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020 07 01; 26(13):3345-3359. Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. PMID: 32193227; PMCID: PMC7334097.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    25. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 03; 19(3):755-764. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. PMID: 31974273; PMCID: PMC7450492.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    26. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation. Clin Cancer Res. 2020 06 01; 26(11):2693-2703. Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA. PMID: 31932491; PMCID: PMC7538010.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    27. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. PMID: 31848196; PMCID: PMC7024675.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    28. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat Commun. 2019 12 05; 10(1):5546. Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Luis Callejas-Valera J, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS. PMID: 31804466; PMCID: PMC6895221.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    29. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491. Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. PMID: 30936880; PMCID: PMC6431643.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    30. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. PMID: 30814108; PMCID: PMC6635035.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    31. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Front Oncol. 2018; 8:435. Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB. PMID: 30386736; PMCID: PMC6199376.
      View in: PubMed   Mentions: 10  
    32. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. Clin Cancer Res. 2018 10 15; 24(20):5058-5071. Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG. PMID: 29898992; PMCID: PMC6532976.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimalsCells
    33. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunol Res. 2018 04; 6(4):422-433. Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW, Pardoll DM, Drake CG. PMID: 29472271; PMCID: PMC6215542.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    34. Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. JAMA Oncol. 2018 Jan 01; 4(1):120-122. Bryant AK, Huynh-Le MP, Simpson DR, Gupta S, Sharabi AB, Murphy JD. PMID: 28975226; PMCID: PMC5833643.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    35. Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. Ann Thorac Surg. 2018 Feb; 105(2):425-431. Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, Daly ME, Murphy JD. PMID: 29198624.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):478-485. Bryant AK, Mudgway R, Huynh-Le MP, Simpson DR, Mell LK, Gupta S, Sharabi AB, Murphy JD. PMID: 29102276.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. Immunotherapy and radiation in glioblastoma. J Neurooncol. 2017 Sep; 134(3):531-539. Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. PMID: 28567588.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    38. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027; PMCID: PMC5469598.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    39. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930; PMCID: PMC5647162.
      View in: PubMed   Mentions: 416     Fields:    Translation:Humans
    40. Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review. PLoS One. 2016; 11(7):e0156489. Green G, Carmona R, Zakeri K, Lee CH, Borgan S, Marhoon Z, Sharabi A, Mell LK. PMID: 27383192; PMCID: PMC4934683.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. PMID: 27376138; PMCID: PMC4927845.
      View in: PubMed   Mentions: 11  
    42. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015 Oct; 16(13):e498-509. Sharabi AB, Lim M, DeWeese TL, Drake CG. PMID: 26433823.
      View in: PubMed   Mentions: 322     Fields:    Translation:HumansAnimalsCells
    43. A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients. Med Phys. 2015 Jul; 42(7):4329-37. Robertson SP, Quon H, Kiess AP, Moore JA, Yang W, Cheng Z, Afonso S, Allen M, Richardson M, Choflet A, Sharabi A, McNutt TR. PMID: 26133630.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    44. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park). 2015 May; 29(5):331-40. Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL. PMID: 25979541; PMCID: PMC4814161.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    45. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015 Apr; 3(4):345-55. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. PMID: 25527358; PMCID: PMC4390444.
      View in: PubMed   Mentions: 297     Fields:    Translation:AnimalsCells
    46. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014; 2:14. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. PMID: 24883190; PMCID: PMC4039332.
      View in: PubMed   Mentions: 47     Fields:    
    47. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol. 2013 Dec; 4(4):343-51. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. PMID: 24294505; PMCID: PMC3819776.
      View in: PubMed   Mentions: 28  
    48. Current standards and future directions for prostate cancer radiation therapy. Expert Rev Anticancer Ther. 2013 Jan; 13(1):75-88. Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, Eble MJ. PMID: 23259429.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    49. Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells. 2009 Dec; 11(4):523-33. Sharabi AB, Lee SH, Goodell MA, Huang XF, Chen SY. PMID: 20025523; PMCID: PMC2883497.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    50. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells. 2009 Jul; 27(7):1604-15. Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. PMID: 19544467; PMCID: PMC4157827.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    51. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008 Dec 16; 6(12):e316. Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee SH, Chen SY. PMID: 19090621; PMCID: PMC2602725.
      View in: PubMed   Mentions: 38     Fields:    Translation:AnimalsCells
    52. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem. 2005 Jan 07; 280(1):88-93. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. PMID: 15525652.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    53. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci. 2004 Mar 15; 117(Pt 8):1319-28. Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W, Knöfler M, Andreae F, Wagner O, Quaranta V, Desoye G. PMID: 15020672.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    54. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J. 2004 Feb; 18(2):364-6. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, Quaranta V. PMID: 14688206.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    55. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003 Apr 18; 303(4):1012-7. Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P. PMID: 12684035.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    56. Discrete proteolysis of focal contact and adherens junction components in Porphyromonas gingivalis-infected oral keratinocytes: a strategy for cell adhesion and migration disabling. Infect Immun. 2002 Oct; 70(10):5846-56. Hintermann E, Haake SK, Christen U, Sharabi A, Quaranta V. PMID: 12228316; PMCID: PMC128337.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    57. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J Cell Biol. 2001 04 30; 153(3):465-78. Hintermann E, Bilban M, Sharabi A, Quaranta V. PMID: 11331299; PMCID: PMC2190561.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Andrew's Networks
    Concepts (285)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (70)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-1-g3264e86e on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California